A view of paediatric outcomes research by Rothberg, Alan D
ORIGINAL ARTICLES
785
October 2005, Vol. 95, No. 10  SAMJ
References 
1. Schneider H, Blaauw D, Dartnall E, et al. STD care in the South African private health sector.
S Afr Med J 2001; 91: 151-156.
2. Connolly AM, Wilkinson D, Harrison A, Lurie M, Abdool Karim SS. Inadequate treatment for
sexually transmitted diseases in the South African private health sector. Int J STD AIDS 1999;
10: 324-327.
3. Chabikuli N, Schneider H, Blaauw D, et al. Equity in the provision of private primary care:
the case of sexually transmitted diseases in South Africa. Health Policy Plan 2002; 17: suppl 1,
40-46.
4. Wilkinson D, Abdool Karim SS, Lurie M, Harrison A. Public-private health sector
partnerships for STD control in South Africa – perspectives from the Hlabisa experience. 
S Afr Med J 2001; 91: 17-20.
5. Department of Health. HIV/AIDS and STD Strategic Plan for South Africa: 2000 - 2005. Pretoria:
DOH, 2000.
6. Brugha R, Zwi A. Sexually transmitted disease control in developing countries: the challenge
of involving the private sector. Sex Transm Infect 1999; 75: 283-285.
7. Madden JM, Quick JD, Ross-Degnan D, Kafle KK.  Undercover careseekers: Simulated clients
in the study of health provider behaviour in developing countries.  Soc Sci Med 1997; 45:
1465-1482.
8. Franco LM, Daly CC, Chilongozi D, Dallabetta G. Quality of case management of sexually
transmitted diseases: comparison of the methods of assessing the performance of providers.
Bull World Health Organ 1997; 75: 523-532.
9. Schneider H, Chabikuli N, Blaauw D, Funani I, Brugha R. Improving the quality of STI care
by private general practitioners: A South African case study. Sex Transm Infect (in press).
Accepted 10 June 2005.
A view of paediatric outcomes research
Alan D Rothberg 
Costs of health care in the 21st century are on the increase.
Whether delivering previously unavailable primary care to
developing communities, treatment for resurgent malaria and
tuberculosis in Africa, antiretrovirals for rampant HIV in the
Third World, or newly developed technology and drugs to
treat diseases of lifestyle and degeneration in affluent societies,
health funding systems are having to decide on what is
affordable.  To make the necessary decisions one requires
health economic data in the form of cost-effectiveness and/or
cost-utility analyses.1 The former provide information on the
costs of achieving a clinical endpoint such as blood pressure
reduction, whereas the latter typically inform on the costs per
quality-adjusted life-year (QALY) gained.
By using QALYs one is able to assess clinical, economic and
humanistic outcomes, and convert the results into a value that
can be compared with other treatments for the same clinical
situation, or even with other conditions altogether (Figs 1 
and 2).  One can, for example, look at the QALYs gained as a
result of neonatal intensive care for 1 000 g babies and compare
these with QALYs gained through placement of drug-eluting
stents for the treatment of coronary artery disease, potentially
enabling decision makers to rank one above the other when it
comes to prioritisation of health care expenditure.  This all
sounds relatively simple and straightforward; however before
we can ask whether we can afford what we are doing it is
imperative that we know what we are actually achieving in
various clinical situations.
There is usually a far greater demand for health economic
information around complex, chronic and potentially costly
problems than is the case for simple, short-term, inexpensive
interventions, and one should therefore note that there are
some very real issues in paediatrics.  For example, and as
shown in Figs 1 and 2, real costs in paediatrics extend way
beyond the patient.  Parents are involved to a greater or lesser
extent, and depending on the chronicity and severity of the
child’s problem, employers may be affected through lost time
and productivity.  There may also be costs to society for
institutional care and/or lost productivity on the part of the
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Fig. 1. Measuring value in health care.
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Fig. 2. Economic parameters in cost utility analyses.
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patient.  As shown in a recent meta-analysis covering 150
paediatric health economic reviews, long-term costs and
outcomes are typically measured extremely poorly, and
parental impact is underestimated.2
‘Scope of practice’ is a limiting factor
Whereas in some cases adverse outcomes manifest soon after a
clinical intervention (e.g. retinopathy of prematurity after
oxygen exposure3) and it is relatively easy to abandon or
modify the particular treatment, in other cases it takes years
before unacceptable patterns emerge.  Examples of the latter
would be the development of gynaecological cancers in
daughters of women treated with diethylstilbestrol (DES)
during pregnancy,4 or malignancy developing years after
cervical irradiation as practised some decades ago for
reduction of adenotonsillar hypertrophy.5 The latter example is
also important because it brings into play a particular problem
in the field of paediatric outcomes research, i.e. the practitioner
who diagnoses and treats the malignancy is unlikely to be the
doctor who prescribed the original treatment.
This dissociation between the original and subsequent health
care provider is aggravated in this country by so-called ‘scope
of practice’.  While legislation confines specialist practice to
each specialty or related specialties, the Health Professions
Council of South Africa (HPCSA) is silent on age cut-offs for
paediatrics;6 however, conventions in both the private and
public sectors have limited the extent to which paediatricians
may continue to treat and follow up their patients.  Medical
schemes in particular apply restrictions and will often
automate administrative processes to reject claims submitted
by paediatricians for patients above a certain age (with
different schemes applying different age cut-offs).  The
implication of the above is that experts in the field of
congenital heart disease, paediatric renal disease, cystic fibrosis
and other metabolic defects are systematically denied the
opportunity to track long-term outcomes, while the patients
themselves are subjected to follow-up by doctors who, by their
own admission, are often not comfortable managing the
original condition or its residual problems.  Under such
circumstances it is highly unlikely that reliable cost-utility
analyses will emerge that will adequately cover all the costs
and outcomes of more complex paediatric problems in the
required manner. 
The scope-of-practice restrictions as applied between
disciplines can also be restrictive within the discipline of
paediatrics as a result of subspecialisation.  This means that the
discontinuity of care found between paediatricians and
physicians may also exist between specialist neonatologists and
paediatricians.  One also cannot ignore the fact that
paediatricians lose contact with patients as a result of
relocation, transfer to care by general practitioners or later on
to care by specialists considered by the parents or patients to be
more age appropriate.  As a result of the above, horizons
become even more limited, follow-up more difficult and, all too
often, early survival becomes the only practical measure of
outcome.  Consequently, as with the DES experience, those
who were involved in the initial care of patients may not see
outcome patterns emerging and it may take time before
harmful practices are modified or interventions abandoned.
Survival is a poor proxy for outcome in
paediatrics 
Neonatal surgery for complex problems represents an area in
which long-term follow-up is obligatory, yet the paediatric
literature abounds with reports that still only present survival
figures.  The question is always whether better survival
statistics between units or after modifications to a procedure
truly represent better outcomes.  Management of congenital
diaphragmatic hernia (CDH) is a case in point – here, poor
survival after patient stabilisation with ECMO (extracorporeal
membrane oxygenation)7 was followed by a shift to less
aggressive stabilisation of the affected neonate by means of
‘permissive hypercapnoea’.8 No one can dispute that survival
statistics of ±75%8 are much better than the 37% with ECMO,7
but where are the data to show that neurodevelopmental
outcome was not adversely affected by the prolonged
hypercapnoea and moderate acidosis related to the
intervention strategy?
Aggressive and creative cardiothoracic surgery for complex
congenital heart diseases has also provided parents with hope
of survival in previously hopeless situations, but this
represents another difficult area in outcomes research because
procedures are constantly being modified and it is difficult to
equate outcomes after the original procedure with those
achieved after three or four modifications.  As with the CDH
and ECMO example, survival of patients with hypoplastic
ventricles may be considerably better after modifications to the
likes of the Norwood and Fontan procedures,9 but continued
follow-up is required to confirm that the previously poor
cardiac and neurodevelopmental outcomes10 are improving to
the same extent.  Clearly what we need and are striving for in
these difficult situations is a set of clinical guidelines that spell
out ‘best practice.’
What is ‘best practice’?
Clinical guidelines are typically developed around what
current evidence and opinion regard as the best way to manage
a particular problem.  In general one accepts that today’s best
practice might be replaced by a better alternative tomorrow,
but there are also situations where best practice of the day has
turned out to be harmful.  Paediatric examples of this would be
unrestricted oxygen therapy that was subsequently linked to
retrolental fibroplasias,3 or an early rotavirus vaccine that was
later linked to intussusception.11 These examples reinforce the
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obligation of paediatricians to be vigilant when introducing
new interventions, but it is equally important that we
constantly monitor and evaluate accepted best practice and ask
whether we are in fact achieving the best outcomes.
One paediatric situation that comes to mind with regard to
monitoring accepted practice is the fairly standard use of
unrestricted oxygen for neonatal resuscitation, and the general
belief that short-term oxygen exposure is benign.  This belief
should perhaps be tempered by experimental and clinical
evidence of hyperoxia-related reperfusion injury to the brain
after asphyxia.12 In spite of fairly extensive research that has
supported their cause,13,14 the proponents of air versus oxygen
resuscitation have not been taken too seriously, perhaps
because for most practitioners abnormal neurodevelopment
after oxygen resuscitation would be attributed to the asphyxia
and not the oxygen.  However, it could also be that those who
manage resuscitation units fear that withholding oxygen from
newborns who do need it (because of lung disease) would be
more harmful than providing it to those (with apnoea) who do
not.  Perhaps it is only a matter of time before this appears as a
medicolegal issue with parents of a brain-damaged infant
complaining that unrestricted oxygen was a contributing factor.  
Another area in which best practice might be challenged is
the management of small-for-gestational-age (SGA) neonates.
The Barker hypothesis proposes that impaired intrauterine
growth impacts on organs such as the pancreas and kidneys,
setting the scene for cardiovascular and metabolic problems in
adulthood.15 Evidence suggests that accelerated early growth
might be detrimental to such infants,16 yet there is little that is
more satisfying to most new parents and their chosen
paediatricians than rapid weight gain in an infant born several
hundred grams below the norm.  Disciples of the Barker
hypothesis are again in the minority, perhaps for the same
reason as in the air versus oxygen debate – i.e. if too much is
bad, what is the appropriate requirement for early weight
gain? Should one aim to keep these SGA infants low on the
growth charts or allow them to cross percentiles but at a slower
pace?  These questions, and the fact that the patient will be
many years beyond the neonatologist’s scope of practice
if/when adverse consequences emerge, almost certainly mean
that in this instance ‘best practice’ will continue as is.
However, evidence is accumulating that might persuade
paediatricians to become more accountable for changes that
take place in adulthood. 
An excellent role model for acceptance of long-term
responsibility would be the Liggins Institute, which has
committed to following up interventions such as the
administration of steroids to mothers in preterm labour to
stimulate surfactant production and prevent hyaline membrane
disease in the infant.  The original studies were done in the
1970s, and the 30-year follow-up has recently been published.17
Results are reassuring in terms of clinical expression of
cardiovascular disease in the offspring, but the metabolic
studies confirm that changes have indeed taken place, and
continued follow-up is therefore necessary to explore whether
diabetes will be a problem in the future.  Another example of
long-term responsibility is the emergence of dedicated units for
management of ‘grown-ups with congenital heart disease’
(GUCH units).  These units are focused on continuity of care,
recognising the need to engage paediatric and adult
practitioners from clinical and psychosocial disciplines.18,19
Cynics might argue that best practice is a medicolegal
concept and not a clinical one, serving as a defence for
practitioners who did what most others were doing at a
particular time rather than challenging them to evaluate
individual and communal practices continuously to ensure that
their interventions have indeed produced the best clinical,
economic and humanistic outcomes.  From a clinical
perspective the term ‘best practice’ can confidently be applied
only when we are certain that a patient’s original problem has
been fully treated by means of a specific intervention that has
no broader effects.  Ligation of an isolated patent ductus
arteriosus can probably be regarded as definitive best practice
while, as per the Liggins Institute example, one must consider
that the jury is still out on the use of steroids for prevention of
hyaline membrane disease.  After all, in the latter situation one
is using a potent hormone with diverse actions to achieve a
specific result in an immature, developing organism.  Under
such circumstances how can one possibly be confident that
there will not be any clinical spillover, and how can one do
anything but commit to a programme of long-term
observation? 
No article on paediatric outcomes is complete without
specific mention of follow-up of premature infants born at the
limits of extrauterine viability.  Suffice it to say that the
administration of steroids as mentioned above is but one of
several such interventions; however the requirement for
follow-up is greater because these infants are even less mature
at the time of exposure to potentially damaging agents and
therapeutic modalities.  
Conclusions
Paediatric outcomes research that includes QALY-type cost
utility analyses is not only important from the point of view of
affordability of interventions for the multitude of complex
problems that occur during gestation or early in life, but it also
provides insight into the quality of life and satisfaction of
patients and their parents.  This is a poorly developed area in
paediatric practice and some reasons for the underdevelop-
ment have been addressed in this review, together with some
clinical examples.  True and total care of children requires
clinical audits, commitment to follow-up and intra- and
interdisciplinary collaboration, paying attention to all relevant
outcomes – clinical, economic and humanistic.  Long-term
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vigilance is necessary unless there is absolute certainty that an
intervention has fulfilled all criteria for ‘best practice’ and an
underlying problem has been treated with complete return to
normality.  Under other circumstances it is necessary to counsel
parents, advise on appropriate preventive and promotive
strategies and get their buy-in for the ‘long haul.’  External
parties should not inhibit this process by introducing arbitrary
scope-of-practice limitations, and medical schemes should be
encouraging rather than obstructing follow-up where it is
necessary. 
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